Ask most people what tesamorelin does and you'll get an answer about belly fat. Ask a neurologist who was reading journals in 2012 and you may get a different one: for a brief period, this growth hormone-releasing hormone (GHRH) analogue was one of the more interesting cognition candidates in ageing research. A randomised, placebo-controlled trial in 152 older adults reported better executive function after 20 weeks. Fourteen years later, a double-blind pilot published in 2026 tried to look again — in 22 people — and found nothing on its planned measures.

That gap is the real story in tesamorelin research on cognition, and it's the part almost never mentioned when the peptide is discussed online. If you're new to the compound, start with our tesamorelin profile for the approval and mechanism basics, then come back for the brain data.

What is tesamorelin, and why would it touch cognition at all?

Tesamorelin is a stabilised analogue of human GHRH. It doesn't supply growth hormone; it prompts the pituitary to release its own, in a pattern closer to normal pulsatility than injected somatropin. Downstream, IGF-1 rises.

The cognitive rationale comes from two directions. GH and IGF-1 signalling declines with age and both cross into the central nervous system, where IGF-1 receptors are dense in the hippocampus. Separately, researchers have hypothesised that GHRH itself may act on the brain through routes that don't depend on the GH/IGF-1 rise it triggers. That second hypothesis is still a hypothesis — it has never been demonstrated cleanly in humans.

The 2012 trial: a real signal, in one centre

The trial everyone cites was run at the University of Washington and published in Archives of Neurology (now JAMA Neurology) in 2012. It randomised 152 adults aged 55–87 — 82 cognitively normal, 66 with amnestic mild cognitive impairment (MCI) — to 1 mg tesamorelin or placebo, self-injected nightly for 20 weeks.

The findings, as reported:

  • A favourable treatment effect on executive function (P = .005)
  • A trend only for verbal memory (P = .08) — that is, not statistically significant
  • IGF-1 up 117%, but staying within the physiological range
  • Body fat percentage down 7.4%

Worth noting what this was and wasn't. It was properly blinded and placebo-controlled, which is more than most peptide cognition claims can offer. It was also a single site, of modest size, with a composite cognitive outcome, and the drug and placebo were supplied free by the manufacturer, Theratechnologies, while the funding came from the NIH/NIA and the US Department of Veterans Affairs. A companion magnetic resonance spectroscopy analysis from the same programme reported changes in brain GABA and myo-inositol — mechanistically suggestive, but a small imaging sub-study, not confirmation of a clinical benefit.

The 2026 pilot: 22 people, and no groupwise effect

The newest entry is a double-blind, placebo-controlled pilot published in eNeurologicalSci in 2026, from the University of Texas Medical Branch at Galveston (registered as NCT02553603 — a named academic sponsor, which matters given how many peptide "trials" circulating online turn out to be registry noise). Twenty-two participants, spanning normal cognition to MCI, took low-dose tesamorelin 1 mg or placebo for 10 weeks. The investigators measured body composition, fatigue, sleep, physical performance, glucose tolerance, cognition, and brain morphometry and functional connectivity.

The result: low-dose GHRH was not associated with significant changes on the study's measures. In exploratory machine-learning analyses the authors flagged possible treatment-related differences in the right anterior cingulate and left superior fronto-occipital fasciculus — interesting, hypothesis-generating, and explicitly not a confirmed effect. With 22 participants and half the treatment duration of the 2012 study, the honest reading is that this pilot was not built to detect the effect the earlier trial reported. It neither confirms nor refutes it.

And the trial in between

Between those two sits a 2025 paper in The Journal of Infectious Diseases (Ellis et al., NIH-funded, UC San Diego). It tested tesamorelin 2 mg daily for six months against standard of care in people with HIV and abdominal obesity, asking whether cutting visceral fat would improve neurocognitive performance. Enrolment stopped early at 73 participants because of slow accrual. Waist circumference fell more with tesamorelin (median difference −2.7 cm, P = .015). Cognition showed a within-group trend in the treated arm (P = .060) but the between-group difference was not significant (P = .673). The design was open-label with no placebo — a serious limitation for cognitive endpoints, where expectation effects are well documented.

So: one positive blinded trial in 152 people, one underpowered open-label trial in 73 that didn't separate the groups, and one 22-person blinded pilot that found nothing on its primary measures. No approved GHRH analogue exists anywhere in the world for cognition, MCI or dementia, and nothing in this literature comes close to supporting one.

Is tesamorelin legal in Australia, and where does it sit for cognition claims?

Tesamorelin has been FDA-approved in the United States since 2010, under the brand name Egrifta, for one indication only: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The European application was withdrawn before approval in 2012, so it has never been EMA-approved.

In Australia, tesamorelin is not listed on the ARTG. There is no Australian-approved tesamorelin product for any indication — HIV lipodystrophy included, let alone cognition. Unapproved therapeutic goods can only reach Australian patients through pathways such as the Special Access Scheme, an Authorised Prescriber arrangement or the Personal Importation Scheme, all of which sit with a treating doctor, not a consumer. Promoting a prescription substance to the public is separately restricted under Australian therapeutic goods advertising rules — which is why "peptide clinic" marketing that gestures at memory or brain benefits deserves scepticism on regulatory grounds before you even reach the evidence.

For athletes, the position is unambiguous: GHRH analogues, tesamorelin named among them, sit in WADA category S2 and are prohibited at all times, in and out of competition. That applies to any Australian competing under a Sport Integrity Australia-administered anti-doping policy.

If you want the broader map of which peptides have real human data and which are running on preclinical fumes, our peptides index tracks each compound separately. And you can join the free updates list if you'd like new trial readouts and TGA developments summarised as they land.

The takeaway

The cognition file on tesamorelin is not empty and it is not settled. It is one credible 2012 signal that has now sat un-replicated for well over a decade, with the two subsequent attempts both too small or too loosely designed to settle the question. That is a genuinely open research thread — not a benefit, and not a reason to act.

FAQ

What is tesamorelin used for?

Tesamorelin is a GHRH analogue approved in the United States (as Egrifta) since 2010 for one use only: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Every other application, including cognition, is investigational.

Does tesamorelin improve memory or cognition?

Not established. A blinded 2012 trial in 152 older adults found improved executive function and a non-significant memory trend, but a 2025 open-label trial in 73 people with HIV showed no between-group cognitive difference, and a 22-person blinded 2026 pilot found no significant changes on its planned measures.

Is tesamorelin legal in Australia?

Tesamorelin is not on the ARTG, so there is no approved Australian product. Access to unapproved therapeutic goods is only via prescriber-led pathways such as the Special Access Scheme, Authorised Prescriber arrangements or personal importation.

Is tesamorelin banned in sport?

Yes. GHRH analogues including tesamorelin fall under WADA's S2 category and are prohibited at all times, both in and out of competition.

Sources

This article is independent editorial information, not medical advice. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, was never EMA-approved, and is not on the ARTG in Australia; no GHRH analogue is approved anywhere for cognition. Speak to a qualified Australian health professional about your own situation.